[{"orgOrder":0,"company":"ECI Pharmaceuticals LLC","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"ECI Pharmaceuticals LLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ECI Pharmaceuticals LLC \/ ECI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ECI Pharmaceuticals LLC \/ ECI Pharmaceuticals"},{"orgOrder":0,"company":"ECI Pharmaceuticals LLC","sponsor":"AiPing Pharmaceutical Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"ECI Pharmaceuticals LLC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ECI Pharmaceuticals LLC \/ ECI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ECI Pharmaceuticals LLC \/ ECI Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by ECI Pharmaceuticals LLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Cialis®, and the generic equivalent Tadalafil, is in a class of medications called phosphodiesterase (PDE) inhibitors. Tadalafil is used to treat erectile dysfunction and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 10, 2021

                          Lead Product(s) : Tadalafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Recipient : Qilu Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : According to IQVIA data for the 12 months ended December 2020, total U.S. generic sales of Ibuprofen tablets 400 mg, 600 mg, 800 mg was approximately $110 million. Generic Folic Acid tablets 1 mg were approximately $20 million for the same period.

                          Brand Name : Ibuprofen-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 23, 2021

                          Lead Product(s) : Ibuprofen

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : AiPing Pharmaceutical Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank